Revolution Medicines, Inc.
RVMD
$149.94
$4.222.90%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 64.86% | 66.22% | 61.16% | 50.55% | 50.92% |
| Gross Profit | -64.86% | -66.22% | -61.45% | -50.85% | -52.81% |
| SG&A Expenses | 139.93% | 101.64% | 79.65% | 62.33% | 52.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.68% | 71.48% | 65.02% | 55.82% | 48.40% |
| Operating Income | -75.68% | -71.48% | -65.22% | -56.02% | -49.69% |
| Income Before Tax | -96.45% | -88.28% | -69.70% | -55.49% | -43.15% |
| Income Tax Expenses | -- | -- | -319.53% | 78.63% | 78.63% |
| Earnings from Continuing Operations | -96.66% | -88.52% | -69.47% | -56.40% | -44.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.66% | -88.52% | -69.47% | -56.40% | -44.03% |
| EBIT | -75.68% | -71.48% | -65.22% | -56.02% | -49.69% |
| EBITDA | -76.10% | -71.98% | -65.69% | -56.41% | -49.94% |
| EPS Basic | -76.93% | -65.84% | -44.24% | -23.49% | -6.30% |
| Normalized Basic EPS | -76.74% | -65.64% | -52.11% | -28.83% | -10.76% |
| EPS Diluted | -76.93% | -65.84% | -44.24% | -23.49% | -6.30% |
| Normalized Diluted EPS | -76.74% | -65.64% | -52.11% | -28.83% | -10.76% |
| Average Basic Shares Outstanding | 11.34% | 13.75% | 15.96% | 23.62% | 32.92% |
| Average Diluted Shares Outstanding | 11.34% | 13.75% | 15.96% | 23.62% | 32.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |